Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 3.1%

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)’s stock price shot up 3.1% during mid-day trading on Friday . The stock traded as high as $19.86 and last traded at $19.86. 4,603 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 1,089,561 shares. The stock had previously closed at $19.27.

Analysts Set New Price Targets

SNDX has been the subject of several analyst reports. JPMorgan Chase & Co. restated an “overweight” rating and set a $34.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 21st. HC Wainwright restated a “buy” rating and set a $41.00 price target on shares of Syndax Pharmaceuticals in a research report on Monday, June 17th. Citigroup cut their price target on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Stifel Nicolaus upped their price objective on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Finally, Scotiabank downgraded shares of Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

Syndax Pharmaceuticals Stock Up 4.0 %

The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -6.23 and a beta of 1.01. The stock’s 50 day moving average price is $20.59 and its two-hundred day moving average price is $21.41.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.11. During the same quarter in the previous year, the company earned ($0.59) EPS. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan acquired 1,250 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average price of $20.03 per share, for a total transaction of $25,037.50. Following the completion of the acquisition, the chief financial officer now owns 52,623 shares of the company’s stock, valued at approximately $1,054,038.69. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.10% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Swiss National Bank raised its position in Syndax Pharmaceuticals by 1.4% in the 3rd quarter. Swiss National Bank now owns 121,000 shares of the company’s stock valued at $1,757,000 after purchasing an additional 1,700 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Syndax Pharmaceuticals by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 506,467 shares of the company’s stock valued at $7,354,000 after purchasing an additional 15,156 shares during the last quarter. Deutsche Bank AG raised its position in Syndax Pharmaceuticals by 13.8% in the 3rd quarter. Deutsche Bank AG now owns 49,813 shares of the company’s stock valued at $723,000 after purchasing an additional 6,037 shares during the last quarter. Qube Research & Technologies Ltd raised its position in Syndax Pharmaceuticals by 57.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 206,394 shares of the company’s stock valued at $2,997,000 after purchasing an additional 75,636 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in Syndax Pharmaceuticals by 8.1% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,000,000 shares of the company’s stock valued at $14,520,000 after purchasing an additional 75,000 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).